Brief: Protara Therapeutics Announces Positive Preliminary Data From Advanced-1 Phase 1A Dose Escalation Trial Of Tara-002 In Nmibc Supporting Advancement Into Phase 2 Clinical Development

Protara Therapeutics

28/04/2023 14:07

April 28 (Reuters) - Protara Therapeutics Inc  TARA.O :
    * PROTARA THERAPEUTICS ANNOUNCES POSITIVE PRELIMINARY DATA
FROM
ADVANCED-1 PHASE 1A DOSE ESCALATION TRIAL OF TARA-002 IN NMIBC
SUPPORTING ADVANCEMENT INTO PHASE 2 CLINICAL DEVELOPMENT
    * PROTARA THERAPEUTICS INC - FAVORABLE TOLERABILITY OBSERVED
IN
PATIENTS WITH NMIBC TREATED WITH TARA-002 IN ADVANCED-1 TRIAL
    * PROTARA THERAPEUTICS INC - ANTI-TUMOR ACTIVITY WAS
OBSERVED IN
ALL THREE EVALUABLE PATIENTS WITH CIS
    * PROTARA THERAPEUTICS INC - MAJORITY OF REPORTED ADVERSE
EVENTS
WERE GRADES 1 AND 2 ACROSS ALL DOSE LEVELS
    * PROTARA THERAPEUTICS INC -  TREATMENT-RELATED ADVERSE
EVENTS
WERE IN LINE WITH TYPICAL RESPONSES TO BACTERIAL
IMMUNOPOTENTIATION
    * PROTARA THERAPEUTICS INC - PATIENT ENROLLMENT IS ONGOING
IN
OPEN-LABEL EXPANSION TRIAL (ADVANCED-1EXP)
    * PROTARA THERAPEUTICS INC - ADVANCED-2 IS EXPECTED TO
INITIATE IN
SECOND HALF OF 2023

Source text for Eikon:  ID:nGNXpdS76 
Further company coverage:  TARA.O 

 ((Reutersbriefs@thomsonreuters.com;))